dimethylthiambutene

Dimethylthiambutene is a synthetic opioid analgesic of the thiambutene class. It was developed in the United Kingdom in the late 1940s and introduced to market by Burroughs-Wellcome in 1951. Structurally related to methadone and classified as an open-chain or thienyl derivative opioid, it has been used primarily for moderate pain relief and is most commonly employed in veterinary medicine in Japan. Dimethylthiambutene acts as an agonist at mu-type and delta-type opioid receptors to produce analgesia similar to meperidine but with dependence potential comparable to morphine. The drug is under international control (UN Single Convention on Narcotic Drugs Schedule I) due to its high abuse potential[1][2][4][5].

Brand names

OhtonAminobuteneDimethibutinKobatonTakaton

Other names

3-dimethylamino-1,1-bis(2-thienyl)-1-butene3-dimethylamino-1,1-di-(2'-thienyl)-1-butenedimethylthiambutenumdimetiltiambutenedimetiltiambutenoN,N-dimethyl-4,4-di(2-thienyl)-3-buten-2-amineN,N,1-trimethyl-3,3-di(2-thienyl)allylamineN,N,1-trimethyl–3,3-di(2-thienyl)–2-propenylamine